Navamedic: final agreement with Gruenenthal for CEE

Navamedic, a Norwegian manufacturer of glucosamine-based products, has signed a final agreement with Gruenenthal, a pharma firm of German origin, for marketing and distribution of its glucosamine product Glucomed/Flexove for a range of Central and Eastern Europe (CEE) countries, including Poland.

The agreement was signed for a period of 10 years. The other countries covered by the agreement are the Czech Republic, Belarus, Kazakhstan, Slovakia, Russia and Ukraine. Austria may also be added to the seven countries already covered by the agreement. The companies signed a framework agreement for this market on 10 January, and the final agreement is expected to be formally signed before the end of March 2007.
Gruenenthal has already commenced the regulatory process in countries not part of the EU/EEA product approval process. Product launches are expected from 2007 in EU countries and 2008 in non-EU countries.

Navamedic announced that it had entered into a framework agreement with Gruenenthal on 29 September 2006. Prior to this, the Norwegian firm had been searching for a distribution partner since the product’s first approval at the beginning of the year, Navamedic CEO, Oyvind Brekke, revealed to Pharma Poland News in January 2006.